Payment overview · 2025
General Payments
$183.65
10 reported records · 6 companies
Healthcare provider profile · identity verified
Earic Ramon Bonner, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EDENTON, NC · NPI 1548526411
Verified facts
What the public records show
CMS Open Payments records show Earic Ramon Bonner, M.D. received $183.65 in general payments during 2025 across 10 reported records.
Corcept Therapeutics accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $68.03 | 37.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.94 | 17.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.47 | 16.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.82 | 10.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.73 | 10.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.66 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.65 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $68.03 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 846 | 189 |
| Atorvastatin Calcium | Atorvastatin Calcium | 637 | 160 |
| Hydrochlorothiazide | Hydrochlorothiazide | 488 | 121 |
| Lisinopril | Lisinopril | 414 | 95 |
| Omeprazole | Omeprazole | 407 | 94 |
| Furosemide | Furosemide | 390 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 68 |
| Gabapentin | Gabapentin | 305 | 62 |
| Losartan Potassium | Losartan Potassium | 304 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 283 | 76 |
| Sertraline Hcl | Sertraline Hcl | 246 | 54 |
| Potassium Chloride | Potassium Chloride | 226 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 222 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 47 |
| Simvastatin | Simvastatin | 181 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 42 |
| Xarelto | Rivaroxaban | 159 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 33 |
| Eliquis | Apixaban | 151 | 28 |
| Famotidine | Famotidine | 148 | 39 |
| Spironolactone | Spironolactone | 147 | 35 |
| Glimepiride | Glimepiride | 139 | 37 |
| Allopurinol | Allopurinol | 136 | 30 |
| Carvedilol | Carvedilol | 130 | 30 |
| Clonazepam | Clonazepam | 123 | 21 |
| Meloxicam | Meloxicam | 121 | 25 |
| Montelukast Sodium | Montelukast Sodium | 121 | 25 |
| Metformin Hcl Er | Metformin Hcl | 116 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 106 | 19 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 25 |
| Finasteride | Finasteride | 99 | 17 |
| Januvia | Sitagliptin Phosphate | 94 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 83 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 11 |
| Valsartan | Valsartan | 81 | 20 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 79 | 15 |
| Ezetimibe | Ezetimibe | 74 | 15 |
| Clonidine Hcl | Clonidine Hcl | 73 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 22 |
| Ozempic | Semaglutide | 70 | 13 |
| Irbesartan | Irbesartan | 68 | 14 |
| Jardiance | Empagliflozin | 66 | 11 |
| Lovastatin | Lovastatin | 61 | 14 |
| Mirtazapine | Mirtazapine | 58 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 12 |
| Tradjenta | Linagliptin | 57 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 56 | 12 |
| Atenolol | Atenolol | 55 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 11 |
| Novolog Flexpen | Insulin Aspart | 54 | 11 |
| Pregabalin | Pregabalin | 54 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 54 | 19 |
| Levetiracetam | Levetiracetam | 53 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 53 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | suppressed |
| Prednisone | Prednisone | 49 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 15 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Febuxostat | Febuxostat | 45 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 11 |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 19 |
| Linzess | Linaclotide | 43 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 43 | suppressed |
| Klor-Con M20 | Potassium Chloride | 42 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Belsomra | Suvorexant | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Colchicine | Colchicine | 33 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Klor-Con M10 | Potassium Chloride | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.65 · 10 records | Corcept Therapeutics | Dexcom G6 Transmitter, Korlym, LEQVIO, MOUNJARO, Ozempic, Rybelsus, VOQUEZNA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error